Vera Therapeutics Gets FDA Priority Review for Atacicept and Confirms Funding Through Launch
Key Facts
- •The FDA granted priority review to the Biologics License Application (BLA) for atacicept for the treatment of IgA nephropathy (IgAN).
- •The PDUFA date is set for July 7, 2026, with a potential commercial launch expected in mid-2026.
- •The company stated its balance sheet is sufficient to fund operations beyond the drug's approval and U.S. commercial launch.
Vera Therapeutics (Nasdaq: VERA) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its Biologics License Application (BLA) for atacicept. The drug is designed to treat IgA nephropathy (IgAN), following positive clinical data from the Phase 3 ORIGIN 3 study. The FDA has set a PDUFA action date for July 7, 2026, with a potential commercial launch anticipated in mid-2026. Alongside this regulatory milestone, the company reported its full-year 2025 financial results, highlighting a robust capital position. Vera Therapeutics confirmed that its current balance sheet is sufficient to fund operations well beyond the drug's approval and initial U.S. market entry. This financial stability, supported by recent equity and debt financing, ensures the company can meet its strategic commercialization goals.
freemium.freemium.cta.signup
freemium.freemium.cta.signup_button